WIRB-Copernicus Group snaps up a pair of clinical analytics companies for undisclosed price

virtual clinical trials
Clinical research helper WIRB-Copernicus Group acquired KMR Group and Metrics Consortium to bolster its market insights and intelligence division. (UCB/Science 37)

Clinical research helper WIRB-Copernicus Group (WCG) acquired KMR Group and Metrics Consortium (MCC) in a deal that bolsters the company’s market insights and intelligence division.

Both KMR Group and MCC are focused on clinical trial benchmarking and intelligence. Terms of the acquisitions weren’t disclosed.

“The industry-leading combination of KMR Group and MCC provides our clients unmatched benchmarking data and insights with which to compare their performance with peers,” Donald Deieso, WCG’s chairman and chief executive, said in a statement. “These actionable insights provide clients the advantage of ‘knowing rather than guessing’ in the critical decisions affecting their studies.”


Like this story? Subscribe to FierceBiotech!

Biopharma is a fast-growing world where big ideas come along every day. Our subscribers rely on FierceBiotech as their must-read source for the latest news, analysis and data in the world of biotech and pharma R&D. Sign up today to get biotech news and updates delivered to your inbox and read on the go.

The two latest acquisitions by WCG will operate independently as part of its market insights and intelligence division, the company said.

Last summer, WCG picked up Patient Genesis’ eConsent technology, which features software that uses custom video animations to present clinical trial information and asks patients questions to assess their level of understanding as part of an effort to provide improved patient education and easier enrollment.

Suggested Articles

WIRB-Copernicus launched a product aimed at upping the efficiency of clinical research operators at institutions and independent research sites.

Celgene is paying Exscientia $25 million up front in a three-year discovery deal for three programs in oncology and autoimmunity.

Ovation.io reeled in $5 million in series A funding that it plans to use to accelerate lab deployment and expand other features.